A Phase 2, Multi-center Study to Evaluate the Safety and Efficacy of ABI-007 Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PANC-001
- Sponsors Celgene Corporation
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 10 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
- 08 Jun 2015 Planned End Date changed from 1 Dec 2016 to 1 Oct 2015, as reported by ClinicalTrials.gov.